Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,341 | 119 | 1,203 |
| Samples | 314 | 54 | 254 |
| Peptides | 307 | 42 | 269 |
Function
LGI1 · Leucine rich glioma inactivated 1
This gene encodes a member of the secreted leucine-rich repeat (LRR) superfamily and shares homology with members of the SLIT protein family. The encoded protein may regulate the activity of voltage-gated potassium channels and may be involved in neuronal growth regulation and cell survival. This gene is rearranged as a result of translocations in glioblastoma cell lines, and it is frequently down-regulated or rearranged in malignant gliomas. Mutations in this gene result in autosomal dominant lateral temporal epilepsy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015].
Isoforms & Proteins
9 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000371418 | O95970 | 330 | 238 |
| ENST00000629035 | A0A0D9SFU4* | 277 | 211 |
| ENST00000630047 | O95970-3 | 266 | 203 |
| ENST00000371413 | O95970-2 | 127 | 101 |
| ENST00000636155 | A0A1B0GV33* | 116 | 93 |
| ENST00000630184 | A0A0D9SFH6* | 76 | 60 |
| ENST00000637689 | A0A1B0GVF6* | 75 | 57 |
| ENST00000478763 | A0A0D9SFE3* | 44 | 36 |
| ENST00000627699 | A0A0D9SFS5* | 30 | 26 |
Gene Properties
Recurrent Mutations
All 238 amino-acid changes on canonical ENST00000371418 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LGI1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LGI1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Melanoma | 10/210 5% | 46/1899 2% |
| Endometrial Carcinoma | 4/42 10% | 13/612 2% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Other Solid Cancers | 2/94 2% | 25/1515 2% |
| Colorectal Carcinoma | 14/143 10% | 29/3239 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 7/810 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Rhabdomyosarcoma | 0/33 0% | 2/171 1% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 16/1390 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Ovarian Carcinoma | 2/109 2% | 7/998 1% |
| Bladder Carcinoma | 1/58 2% | 6/956 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 4/752 1% |
| Esophageal Carcinoma | 2/23 9% | 3/769 0% |
| Biliary Tract Carcinoma | 1/54 2% | 5/950 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 13/2550 1% |
| Gastric Carcinoma | 0/74 0% | 10/1809 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Hepatocellular Carcinoma | 0/46 0% | 10/2210 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Breast Carcinoma | 0/144 0% | 15/3264 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Glioma | 0/52 0% | 9/2127 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 4/1592 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 6/2640 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 7/2534 0% |
Mutation Distribution
Where LGI1 is mutated · all tissues, split by cell line vs tissue
How many mutations in LGI1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,341 mutations in LGI1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|